Tumors of the Central Nervous System, Volume 8, 2012
Astrocytoma, Medulloblastoma, Retinoblastoma, Chordoma, Craniopharyngioma, Oligodendroglioma, and Ependymoma
Tumors of the Central Nervous System Series, Vol. 8

Coordinator: Hayat M.A.

Language: English

210.99 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Tumors of the Central Nervous System, Volume 8
Publication date:
Support: Print on demand

210.99 €

In Print (Delivery period: 15 days).

Add to cartAdd to cart
Tumors of the central nervous system. Volume 8. Astrocytoma, medulloblastoma, retinoblastoma, chordoma, craniopharyngioma, oligodendroglioma & ependymoma
Publication date:
347 p. · 17.8x25.4 cm · Hardback
With tens of thousands of new CNS tumor cases each year in the US alone, this series of publications is a valuable aid to the diagnosis and treatment of these problematic neoplasms. Now, the eighth in the set returns to the topic of brain tumors, dealing with seven distinct types: astrocytoma, medulloblastoma, retinoblastoma, chordoma, craniopharyngioma, oligodendroglioma, and ependymoma. After updating the classification of medulloblastoma the volume provides an overview of ependymoma as well as describing the delineation of prognosis based on the genetic aberrations of the latter patients. The material offers key insights into the molecular pathways involved in tumor biology, such as the role of E-cadherin gene instability, carbonic anhydrase II, urokinase plasminogen activator, and Wnt signaling in meningioma. Contributors explain the genetic and clinical features associated with recurring meningioma, including the role played by erythropoietin receptor, and examine the way in which OTX2 transcription factor functions as an oncogene in medulloblastoma. With much more besides, including discussion of the molecular mechanisms that result in resistance to chemotherapy in medulloblastoma, this volume and its companions have a positive role to play in inspiring a new generation of researchers to design new drugs that are better targeted?and thus more effective.

Table of Contents: TCNS Volume 8

Astrocytoma

Chapter 1. astrocytoma cell line: role of brain natriuretic peptide

chapter 2. malignant brain astrocytomas: extent of resection affects survival

medulloblastoma

chapter 3. medulloblastoma: classification (a review)

chapter 4. medulloblastomas: clinically important microrna genes

chapter 5. medulloblastoma: role of otx2 transcription factors

chapter 6. molecular mechanisms of chemoresistance in medulloblastoma

chapter 7. extraneural metastasis in medulloblastoma

Chapter 8. Medulloblastoma: Therapy with Bortezomib/Tumor Necrosis factor-related apoptosis-inducing ligand

chapter 9.standard-risk medulloblastoma: hyperfractionated radiotherapy

retinoblastoma

chapter 10. retinoma and retinoblastoma: genomic hybridisation

chapter 11. cell cycle control by ataxia telangiectasia mutated protein through regulating retinoblastoma protein phosphorylation

chapter 12. role of survivin in retinoblastoma: diagnosis and prognosis

chapter 13. retinoblastoma: the role of epigenetics

chapter 14. retinoblastoma: disease, diagnosis, therapy and management

chapter 15. long-term survivors of retinoblastoma: risk of increased second malignancy

chapter 16. new cancers among long-term survivors of retinoblastoma

chordoma

chapter 17. chordoma: role of cam5.2

chapter 18. chordomas and chondrosarcomas: treatment with particle radiotherapy

chapter 19. skull base chordomas: endonasal endoscopic transclival approach

craniopharyngioma

chapter 20. craniopharyngioma: comparison between supra-orbital versus endonasal keyhole approaches

chapter 21. the expanded endoscopic endonasal approach for primary and recurrent craniopharyngiomas

chapter 22. craniopharyngioma: the role of radiation

chapter 23. cystic craniopharyngiomas: intratumoral bleomycin therapy

oligodendroglioma

chapter 24. anaplastic oligodendroglioma metastasized to extraneural sites

chapter 25. recurrent oligodendroglioma: treatment with bevacizumab

ependymoma

chapter 26. ependymoma: an overview

chapter 27. ependymomas: prognosis based on genetic aberrations

chapter 28. aberrant dna methylation in ependymomas

chapter 29. progressively metastasizing ependymoma: genomic aberrations

chapter 30. extradural ependymoma: diagnosis using magnetic resonance imaging

chapter 31. primary malignant ependymoma of the abdominal cavity: diagnosis

chapter 32. atypical histologic features and patterns of malignant evolution in tanycytic ependymoma

chapter 33. intracranial ependymoma: role for chemotherapy.

New technologies and their applications in tumor diagnosis, treatment, and prognosis are discussed

Methods to assess the effectiveness of cancer treatments are presented

The importance of the quality of life after cancer therapy is pointed out

Molecular profiling of brain tumors to select targeted therapy in clinical trials is explained

A large number of color figures are included